1152617-14-5

Basic information

• Product Name: 3-Pyridinecarbonitrile, 2,4-dibroMo-
• Synonyms: 3-Pyridinecarbonitrile, 2,4-dibroMo-;2,4-DibroMo-nicotinonitrile
• CAS NO: 1152617-14-5
• Molecular Formula: C₆H₂Br₂N₂
• Molecular Weight: 261.90148
• Mol File: 1152617-14-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 362.7±42.0 °C(Predicted)
• Appearance: /
• Density: 2.19±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.69±0.10(Predicted)
• CAS DataBase Reference: 3-Pyridinecarbonitrile, 2,4-dibroMo-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarbonitrile, 2,4-dibroMo-(1152617-14-5)
• EPA Substance Registry System: 3-Pyridinecarbonitrile, 2,4-dibroMo-(1152617-14-5)

Safety Data

• Hazardous Substances Data: 1152617-14-5(Hazardous Substances Data)

Usage

Uses

2,4-Dibromonicotinonitrile

Upstream product

• 21642-98-8 4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile 

Downstream Products

• 727737-51-1 4-(Benzyloxy)-2-bromopyridine-3-carbonitrile 
• 1254981-11-7 2-bromo-3-cyano-4-(4-phenylpiperidin-1-yl)pyridine 
• 1403598-31-1 2-bromo-4-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]pyridine-3-carbonitrile 
• 1254977-57-5 3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-1,2,4-triazolo[4,3-a]pyridine-8-carbonitrile 
• 1254977-79-1 3-(1,1-dimethylethyl)-7-(4-phenyl-1-piperidinyl)-1,2,4-triazolo[4,3-a]pyridine-8-carbonitrile 
• 1254977-68-8 3-(methoxymethyl)-7-(4-phenyl-1-piperidinyl)-1,2,4-triazolo[4,3-a]pyridine-8-carbonitrile 
• 1254981-12-8 [3-cyano-4-(4-phenylpiperidin-1-yl)pyridin-2-yl]hydrazine 
• 1254981-13-9 7-(4-phenylpiperidin-1-yl)[1,2,4]triazolo[4,3-a]pyridine-8-carbonitrile 
• 1254977-54-2 3-ethyl-7-(4-phenyl-1-piperidinyl)-1,2,4-triazolo[4,3-a]pyridine-8-carbonitrile 
• 1254977-72-4 7-(4-phenyl-1-piperidinyl)-3-propyl-1,2,4-triazolo[4,3-a]pyridine-8-carbonitrile 
• 1254977-64-4 7-(4-phenyl-1-piperidinyl)-3-(2,2,2-trifluoroethyl)-1,2,4-triazolo[4,3-a]pyridine-8-carbonitrile 

Relevant articles and documents

Imidazo[1,2-a]pyridines: Orally active positive allosteric modulators of the metabotropic glutamate 2 receptor

Advanced leads of an imidazopyridine series of positive allosteric modulators of the metabotropic glutamate 2 (mGlu2) receptor are reported. The optimization of in vitro ADMET and in vivo pharmacokinetic properties led to the identification of 27o. With g

7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.